<DOC>
	<DOCNO>NCT02967289</DOCNO>
	<brief_summary>The trial phase III , multicenter , open-labeled randomize trial compare association 5-fluorouracil , folinic acid , irinotecan oxaliplatin ( mFOLFIRINOX ) versus oxaliplatin , folinic acid , 5FU ( mFOLFOX 6 ) chemotherapy protocols patient high-risk stage III colon cancer adjuvant setting .</brief_summary>
	<brief_title>IRinotecan Oxaliplatin Colon Cancer Adjuvant Setting</brief_title>
	<detailed_description>After inclusion non-inclusion criterion fulfil patient consent obtain , patient include randomize trial.The maximum delay allow signature consent form patient randomization study 28 day . The randomization procedure use minimization method allocate treatment mFOLFIRINOX mFOLFOX 6 1:1 ratio , stratify follow criterion : - Perforation urgent surgery versus perforation urgent surgery - T1-T3N2 v T4aN1 versus T4bN1 versus T4N2 - Right colon ( right splenic flexure ) v leave colon - Country ( France v Canada ) Patient eligible sign informed consent randomize one two treatment arm receive every 14 day treatment duration 12 cycle . Arm A : mFOLFIRINOX Arm B : mFOLFOX 6</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1.Patient ≥18 year &lt; 71years 2.Patient ECOG ≤1 3.Pathologically confirm highrisk stage III colon adenocarcinoma , restrict pT4N1 pT14N2 tumor . 4.Curative R0 surgical resection within 42 day randomization . 5.Patients undergone surgery colon cancer , define tumor location &gt; 12 cm anal verge endoscopy and/or peritoneal reflection surgery ( high rectum ) , without gross microscopic evidence residual disease surgery curative intent 6.Start study drug treatment perform less 56 day surgery . 7.No prior chemotherapy . 8.No prior abdominal pelvic irradiation . 9.Patient adequate organ function : Absolute neutrophil count ( ANC ) ≥ 2 x 109/L Haemoglobin ≥9 g/dL Platelets ( PTL ) ≥100 x 109/L AST/ALT ≤2.5 x ULN Alkaline phosphatase ≤2.5 x ULN Total Bilirubin ≤1.5 x ULN ( Upper Limit Normal ) Creatinine clearance ≥50 mL/min ( Cockcroft Gault formula ) Kalemia , magnesemia , calcemia ≥ 1 LLN ( Lower Limit Normal ) Carcinoembryogenic antigen ( CEA ) ≤10ng/mL surgery ( screen period ) 10.Adequate contraception applicable . 11.Patient able willing comply study procedure per protocol 12.Patient able understand willing sign date write voluntary informed consent form screen visit prior protocolspecific procedure 13.Public private health insurance coverage 14.Life expectancy &gt; = 5 year 1.Major surgical procedure , open biopsy significant traumatic injury within 28 day prior study treatment start . Incompletely heal wound anticipation need major surgical procedure course study 2.Metastatic disease 3.Presence inflammatory bowel disease and/or ileus 4.Known hypersensitivity reaction component study treatment . 5.Pregnancy ( absence confirm βhCG test ) breastfeeding period 6.Clinically relevant coronary artery disease history myocardial infarction last 12 month , high risk uncontrolled arrhythmia ( men : QT/QTc ≥450 msec , woman : QT/QTc ≥470 msec ) 7.Previous malignancy last 5 year except curative treat basal cell carcinoma skin and/or situ carcinoma cervix 8.Medical , geographical , sociological , psychological legal condition would permit patient complete study sign inform consent 9.History current evidence physical examination central nervous system disease peripheral neuropathy ≥ grade 1 Common Toxicity Criteria Adverse Events ( CTCAE ) v4.03 . 10.Any significant disease , investigator 's opinion , would exclude patient study . 11.Known DPD deficiency UGT1A1 homozygous 7/7 12.Patients already include another therapeutic trial involve experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>colon</keyword>
	<keyword>cancer</keyword>
	<keyword>stage 3</keyword>
	<keyword>high-risk</keyword>
	<keyword>mFolfirinox</keyword>
	<keyword>mFolfox6</keyword>
	<keyword>adjuvant</keyword>
</DOC>